At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 13 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of HFpEF With Nitrate Supplement: A Double-blind, Placebo Controlled Trial Including Patients With Atrial Fibrillation
In Brief
A Early Phase 1 clinical trial evaluating Active lozenge and Placebo for Heart Failure With Normal Ejection Fraction. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsHumanN
Timeline
Early Ph 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedSep 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedSep 21, 2017
Enrollment StartJun 29, 2017
Primary CompletionAug 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.8 years ago
Interventions
Active lozengedietary
nitric oxide generating lozenge
Placebodrug
placebo tablet